Xing Zhe, Liu Jing, Cai Jiazheng, Jiang Xiaofeng, Liang Jingwen, Fujio Masahito, Hadler-Olsen Elin, Wang Jing, Kantarci Alpdogan, Xue Ying
School of Stomatology, Lanzhou University, Lanzhou 730000, China.
Key Laboratory of Dental Maxillofacial Reconstruction and Biological Intelligence Manufacturing, Lanzhou University, Lanzhou 730000, China.
Pharmaceutics. 2024 Dec 25;17(1):16. doi: 10.3390/pharmaceutics17010016.
To evaluate the drug release, cytocompatibility with periodontal ligament cells (PDLCs), and therapeutic efficacy of GelMA hydrogel loaded with resolvin D1 (RvD1) in treating rat periodontal inflammation and alveolar bone damage. An RvD1 complexed with GelMA was prepared, and its release kinetics and compatibility with PDLCs were assessed. Rats with induced periodontitis were treated weekly with topical applications of vehicle, GelMA, RvD1, or RvD1 complexed with GelMA for four weeks. Periodontal inflammation and tissue regeneration were evaluated using quantitative PCR (qPCR) and histochemical staining, while alveolar bone repair and regeneration were analyzed through micro-CT. The RvD1 complexed with GelMA effectively released RvD1 and enhanced the proliferation and viability of PDLCs. Compared to RvD1 alone, treatment with RvD1 complexed with GelMA significantly reduced inflammatory cell infiltration, TNF-α and RANKL expression, and osteoclast formation in periodontal tissues. Additionally, it promoted the expression of specific anti-inflammatory and regenerative markers. Micro-CT analysis confirmed significant new bone formation in the RvD1 complexed with GelMA-treated group. RvD1 complexed with GelMA provides sustained drug release and biocompatibility, effectively resolves periodontal inflammation, and promotes tissue regeneration in periodontitis.
为评估负载消退素D1（RvD1）的甲基丙烯酰化明胶（GelMA）水凝胶在治疗大鼠牙周炎和牙槽骨损伤中的药物释放、与牙周膜细胞（PDLCs）的细胞相容性及治疗效果。制备了RvD1与GelMA的复合物，并评估其释放动力学及与PDLCs的相容性。对诱导性牙周炎大鼠每周局部应用赋形剂、GelMA、RvD1或RvD1与GelMA的复合物，持续四周。使用定量聚合酶链反应（qPCR）和组织化学染色评估牙周炎症和组织再生，通过显微CT分析牙槽骨修复和再生情况。RvD1与GelMA的复合物有效释放RvD1并增强了PDLCs的增殖和活力。与单独使用RvD1相比，用RvD1与GelMA的复合物治疗可显著减少牙周组织中的炎性细胞浸润、肿瘤坏死因子-α（TNF-α）和核因子κB受体活化因子配体（RANKL）表达以及破骨细胞形成。此外，它还促进了特异性抗炎和再生标志物的表达。显微CT分析证实，RvD1与GelMA复合物治疗组有显著的新骨形成。RvD1与GelMA的复合物具有持续药物释放和生物相容性，能有效解决牙周炎症并促进牙周炎中的组织再生。
